• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.动态的域间相互作用有助于组织金属蛋白酶抑制剂对基质金属蛋白酶的抑制作用。
J Biol Chem. 2011 Jun 10;286(23):21002-12. doi: 10.1074/jbc.M110.200139. Epub 2011 Apr 25.
2
Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding the MMP-2 hemopexin C-domain.利用一种新型重组肌红蛋白融合蛋白表达系统,通过诱变来表征金属蛋白酶组织抑制剂(TIMP)-4和TIMP-2的C末端结构域及尾部。酸性残基在结合MMP-2血红素结合蛋白C结构域中的重要性。
J Biol Chem. 2002 Dec 13;277(50):48696-707. doi: 10.1074/jbc.M209177200. Epub 2002 Oct 8.
3
Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.金属蛋白酶组织抑制剂-4通过有效抑制膜型1-基质金属蛋白酶来抑制而非支持明胶酶A的激活。
Cancer Res. 2001 May 1;61(9):3610-8.
4
E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A).TIMP-4的大肠杆菌表达以及与TIMP-1和TIMP-2的比较动力学研究:对TIMP与基质金属蛋白酶2(明胶酶A)相互作用的深入了解。
Biochemistry. 2002 Dec 17;41(50):15025-35. doi: 10.1021/bi026454l.
5
Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes.基质金属蛋白酶-10/TIMP-2 结构与分析定义了 MMP/TIMP 复合物中保守的核心相互作用和多样的外位点相互作用。
PLoS One. 2013 Sep 20;8(9):e75836. doi: 10.1371/journal.pone.0075836. eCollection 2013.
6
Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors.限制金属蛋白酶组织抑制剂-1 N 结构域的特异性;明胶酶选择性抑制剂
Protein Sci. 2007 Sep;16(9):1905-13. doi: 10.1110/ps.072978507. Epub 2007 Jul 27.
7
Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).金属蛋白酶组织抑制剂2(TIMP-2)的序列基序决定了前明胶酶A(proMMP-2)与膜型金属蛋白酶1(MT1-MMP)的结合及激活。
Biochem J. 2003 Jun 15;372(Pt 3):799-809. doi: 10.1042/BJ20021573.
8
Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis.在血管生成的主动脉环模型中,MT1 - MMP和基质金属蛋白酶组织抑制因子对血管消退和存活具有不同的调节作用。
Am J Physiol Cell Physiol. 2009 Aug;297(2):C471-80. doi: 10.1152/ajpcell.00019.2009. Epub 2009 Jun 3.
9
Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth.基于对血红素结合蛋白结构域在肿瘤生长中功能的深入了解,设计新型 MT1-MMP 小分子抑制剂。
Cancer Res. 2012 May 1;72(9):2339-49. doi: 10.1158/0008-5472.CAN-11-4149. Epub 2012 Mar 9.
10
Engineering minimal tissue inhibitors of metalloproteinase targeting MMPs via gene shuffling and yeast surface display.通过基因改组和酵母表面展示工程化最小组织金属蛋白酶抑制剂靶向 MMPs。
Protein Sci. 2023 Dec;32(12):e4795. doi: 10.1002/pro.4795.

引用本文的文献

1
Rubiarbonone C inhibits platelet-derived growth factor-induced proliferation and migration of vascular smooth muscle cells through the focal adhesion kinase, MAPK and STAT3 Tyr signalling pathways.鲁比卡丁酮 C 通过粘着斑激酶、MAPK 和 STAT3 Tyr 信号通路抑制血小板衍生生长因子诱导的血管平滑肌细胞增殖和迁移。
Br J Pharmacol. 2017 Nov;174(22):4140-4154. doi: 10.1111/bph.13986. Epub 2017 Sep 22.
2
Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.选择性功能阻断单克隆人抗体突出了膜型-1基质金属蛋白酶(MT1-MMP)在转移中的重要作用。
Oncotarget. 2017 Jan 10;8(2):2781-2799. doi: 10.18632/oncotarget.13157.
3
Matrix metalloproteinase 14 modulates signal transduction and angiogenesis in the cornea.基质金属蛋白酶14调节角膜中的信号转导和血管生成。
Surv Ophthalmol. 2016 Jul-Aug;61(4):478-97. doi: 10.1016/j.survophthal.2015.11.006. Epub 2015 Dec 2.
4
siRNA knockdown of tissue inhibitor of metalloproteinase-1 in keloid fibroblasts leads to degradation of collagen type I.RNA 干扰技术下调瘢痕成纤维细胞中金属蛋白酶组织抑制剂-1 的表达导致 I 型胶原的降解。
J Invest Dermatol. 2014 Mar;134(3):818-826. doi: 10.1038/jid.2013.396. Epub 2013 Sep 16.
5
Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells.在癌细胞中对功能活跃的、具有侵袭性的膜型基质金属蛋白酶 1(MT1-MMP)酶进行非破坏性和选择性成像。
J Biol Chem. 2013 Jul 12;288(28):20568-80. doi: 10.1074/jbc.M113.471508. Epub 2013 Jun 3.
6
TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain.TIMP-1 在不依赖其 MMP 抑制结构域的情况下诱导 MDCK 细胞发生 EMT 样表型转化。
PLoS One. 2012;7(6):e38773. doi: 10.1371/journal.pone.0038773. Epub 2012 Jun 11.
7
Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis.腹腔内癌症转移中的细胞-细胞和细胞-基质动态。
Cancer Metastasis Rev. 2012 Jun;31(1-2):397-414. doi: 10.1007/s10555-012-9351-2.

本文引用的文献

1
The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function.内源性蛋白酶抑制剂 TIMP-1 的固有蛋白灵活性控制其结合界面并影响其功能。
Biochemistry. 2010 Jul 27;49(29):6184-92. doi: 10.1021/bi902141x.
2
Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.细胞糖基磷脂酰肌醇连接膜型 6 基质金属蛋白酶的生化特性分析。
J Biol Chem. 2010 May 21;285(21):16076-86. doi: 10.1074/jbc.M110.107094. Epub 2010 Mar 22.
3
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.金属蛋白酶组织抑制剂(TIMPs):一个具有结构和功能多样性的古老家族。
Biochim Biophys Acta. 2010 Jan;1803(1):55-71. doi: 10.1016/j.bbamcr.2010.01.003. Epub 2010 Jan 15.
4
The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment.在基于细胞的环境中,一种设计的组织金属蛋白酶抑制剂 (TIMP)-1 对天然膜型 1 基质金属蛋白酶 (MT1-MMP) 的活性。
Cancer Lett. 2010 Apr 1;290(1):114-22. doi: 10.1016/j.canlet.2009.08.029. Epub 2009 Oct 7.
5
Inflammatory proprotein convertase-matrix metalloproteinase proteolytic pathway in antigen-presenting cells as a step to autoimmune multiple sclerosis.抗原呈递细胞中的炎性前蛋白转化酶-基质金属蛋白酶蛋白水解途径是自身免疫性多发性硬化症发病过程中的一个环节。
J Biol Chem. 2009 Oct 30;284(44):30615-26. doi: 10.1074/jbc.M109.041244. Epub 2009 Sep 2.
6
Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.Timp-2 与细胞 MT1-MMP 的结合可刺激癌细胞中促进侵袭的 MEK/ERK 信号通路。
Int J Cancer. 2010 Mar 1;126(5):1067-78. doi: 10.1002/ijc.24690.
7
Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis.髓鞘碱性蛋白异构体的基质金属蛋白酶水解是自身免疫性多发性硬化症中免疫原性肽的一个来源。
PLoS One. 2009;4(3):e4952. doi: 10.1371/journal.pone.0004952. Epub 2009 Mar 20.
8
Proteases: multifunctional enzymes in life and disease.蛋白酶:生命与疾病中的多功能酶
J Biol Chem. 2008 Nov 7;283(45):30433-7. doi: 10.1074/jbc.R800035200. Epub 2008 Jul 23.
9
MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer.MT4-(基质金属蛋白酶17)和MT6-基质金属蛋白酶(基质金属蛋白酶25):一组独特的膜锚定基质金属蛋白酶:特性及其在癌症中的表达
Cancer Metastasis Rev. 2008 Jun;27(2):289-302. doi: 10.1007/s10555-008-9129-8.
10
The regulation of matrix metalloproteinases and their inhibitors.基质金属蛋白酶及其抑制剂的调控
Int J Biochem Cell Biol. 2008;40(6-7):1362-78. doi: 10.1016/j.biocel.2007.12.006. Epub 2007 Dec 24.

动态的域间相互作用有助于组织金属蛋白酶抑制剂对基质金属蛋白酶的抑制作用。

Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.

机构信息

Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA.

出版信息

J Biol Chem. 2011 Jun 10;286(23):21002-12. doi: 10.1074/jbc.M110.200139. Epub 2011 Apr 25.

DOI:10.1074/jbc.M110.200139
PMID:21518756
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3121501/
Abstract

Because of their important function, matrix metalloproteinases (MMPs) are promising drug targets in multiple diseases, including malignancies. The structure of MMPs includes a catalytic domain, a hinge, and a hemopexin domain (PEX), which are followed by a transmembrane and cytoplasmic tail domains or by a glycosylphosphatidylinositol linker in membrane-type MMPs (MT-MMPs). TIMPs-1, -2, -3, and -4 are potent natural regulators of the MMP activity. These are the inhibitory N-terminal and the non-inhibitory C-terminal structural domains in TIMPs. Based on our structural modeling, we hypothesized that steric clashes exist between the non-inhibitory C-terminal domain of TIMPs and the PEX of MMPs. Conversely, a certain mobility of the PEX relative to the catalytic domain is required to avoid these obstacles. Because of its exceedingly poor association constant and, in contrast with TIMP-2, TIMP-1 is inefficient against MT1-MMP. We specifically selected an MT1-MMP·TIMP-1 pair to test our hypothesis, because any improvement of the inhibitory potency would be readily recorded. We characterized the domain-swapped MT1-MMP chimeras in which the PEX of MMP-2 (that forms a complex with TIMP-2) and of MMP-9 (that forms a complex with TIMP-1) replaced the original PEX in the MT1-MMP structure. In contrast with the wild-type MT1-MMP, the diverse proteolytic activities of the swapped-PEX chimeras were then inhibited by both TIMP-1 and TIMP-2. Overall, our studies suggest that the structural parameters of both domains of TIMPs have to be taken into account for their re-engineering to harness the therapeutic in vivo potential of the novel TIMP-based MMP antagonists with constrained selectivity.

摘要

由于其重要的功能,基质金属蛋白酶(MMPs)是多种疾病(包括恶性肿瘤)有前途的药物靶点。MMPs 的结构包括催化结构域、铰链和血红蛋白结构域(PEX),其后是跨膜和细胞质尾部结构域或膜型 MMP(MT-MMP)中的糖基磷脂酰肌醇接头。TIMP-1、-2、-3 和 -4 是 MMP 活性的有效天然调节剂。这些是 TIMP 的抑制性 N 端和非抑制性 C 端结构域。基于我们的结构建模,我们假设 TIMP 的非抑制性 C 端结构域与 MMP 的 PEX 之间存在空间冲突。相反,PEX 相对于催化结构域的一定的可移动性是避免这些障碍所必需的。由于其极其差的缔合常数,并且与 TIMP-2 相反,TIMP-1 对 MT1-MMP 的效率不高。我们特别选择了 MT1-MMP·TIMP-1 对来测试我们的假设,因为抑制效力的任何提高都很容易记录下来。我们对结构域交换的 MT1-MMP 嵌合体进行了表征,其中 MMP-2(与 TIMP-2 形成复合物)和 MMP-9(与 TIMP-1 形成复合物)的 PEX 取代了 MT1-MMP 结构中的原始 PEX。与野生型 MT1-MMP 相比,交换 PEX 嵌合体的各种蛋白水解活性随后被 TIMP-1 和 TIMP-2 抑制。总体而言,我们的研究表明,TIMP 两个结构域的结构参数都必须考虑在内,以便对其进行重新设计,以利用新型具有约束选择性的基于 TIMP 的 MMP 拮抗剂的体内治疗潜力。